Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance

Science Translational Medicine  08 Feb 2012:
Vol. 4, Issue 120, pp. 120ps2
DOI: 10.1126/scitranslmed.3003728

You are currently viewing the abstract.

View Full Text


Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.

View Full Text